| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701720 | Journal of Thoracic Oncology | 2017 | 26 Pages |
Abstract
Lung SABR in tumors larger than 5 cm resulted in high local control rates and acceptable survival outcomes in a patient population with appreciable comorbidity. Patients with interstitial lung disease should be considered a very high-risk population for SABR.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Hilâl MD, Saar MD, Esther J. MD, Max MD, PhD, Wilko F.A.R. PhD, Ben J. MD, PhD, Suresh MD, PhD,